General Information of Synthetic Binding Protein (SBP) (ID: SBP003375)
SBP Name
scFv Efungumab
Synonyms
hsp90 grAB; Mycograb
Molecular Weight 26.5 kDa
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase III
Sequence Length 250
SBP Sequence
>scFv Efungumab
MAEVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYI
NYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTV
SSGGGGSGGGGSGGGGSDVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKA
PKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTK
VDIKRAAALE
3D Structure
Computationally Modelled Structure
Click to Save PDB File
Protein Scaffold Information of This SBP
Scaffold ID PS057
Scaffold Info
[1]
Scaffold Name scFv
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Heat shock protein HSP 90-beta
BTS Info
Inhibitor Cryptococcal Meningitis [ICD-11: 1D01.10]; Breast cancer [ICD-11: 2C6Z] N.A. University of South Alabama; NeuTec Pharma [1]
Clinical Trial Information of This SBP
NCT00217815 Click to show the Detail
Indication Cancer of the Breast
Phase Phase I; Phase II
Title Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer
Status Completed
Sponsor NeuTec Pharma
NCT00324025 Click to show the Detail
Indication Cryptococcal Meningitis
Phase Phase II
Title Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
Status Terminated
Sponsor Novartis Pharmaceuticals
NCT00847678 Click to show the Detail
Indication Cryptococcal Meningitis
Phase Phase II
Title Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
Status Terminated
Sponsor Novartis Pharmaceuticals
References
1 Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.